<DOC>
	<DOCNO>NCT02749968</DOCNO>
	<brief_summary>This study liposomal bupivacaine pain control patient blunt chest wall trauma .</brief_summary>
	<brief_title>Intercostal Liposomal Bupivacaine Management Blunt Chest Wall Trauma</brief_title>
	<detailed_description>The purpose study evaluate efficacy liposomal bupivacaine provide analgesia via paravertebral intercostal nerve block follow significant blunt chest trauma , minimize adverse outcome , length stay overall narcotic use . The primary outcome study compare requirement bupivacaine group standard-of-care group .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Rib Fractures</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Anticipated length stay least 72 hour Blunt chest wall trauma two rib sternal fracture Demonstrated ability achieve &gt; 50 % predict inspiratory capacity base ideal body weight use IS within first 24 hour admission Known allergy bupivacaine Respiratory failure require intubation within 24 hour prior enrollment Known suspect atrioventricular nodal blockade process require cardiology evaluation pacemaker placement Hemodynamic instability ( defined new intravenous vasopressor inotrope requirement mean arterial pressure &lt; 55 mmHg ) Signs active myocardial ischemia nonST elevation MI &gt; 20 rib fracture Weight &lt; 50 kg &gt; 150 kg Pregnancy Incarceration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>